Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or (MPP), technology, with an initial focus on the treatment of eye diseases.
Our MPPs are selectively-sized nanoparticles and have proprietary coatings. We believe that these two key attributes enable even distribution of drug particles on mucosal surfaces and significantly increase drug delivery to target tissues by enhancing mobility of drug particles through mucus and preventing drug particles from becoming trapped and eliminated by mucus.Read More »
Data provided by Nasdaq. Minimum 15 minutes delayed.
|Aug 9, 2018|
Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results
|Aug 8, 2018|
Kala Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference
|Jul 31, 2018|
Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease